Michelle McMurry-Heath (BIO via YouTube)
October 11, 2022 04:25 AM EDTUpdated October 13, 06:43 AM
Bioregnum

Michelle Mc­Mur­ry-Heath washed over­board at BIO as in­dus­try group wres­tles over its fu­ture, hunts new CEO

In the end, the in­ter­nal ten­sions rip­ping at BIO had bare­ly sur­faced in fresh tur­moil then the stormy sur­face wa­ters were smoothed by CEO Michelle Mc­Mur­ry-Heath’s quick ex­it. Late Mon­day came word that she had re­signed from her top post, swap­ping it for an ad­vi­so­ry po­si­tion, and soon af­ter we learned that long­time biotech ex­ec Rachel King would be tak­ing her po­si­tion un­til they can find a full-time re­place­ment.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE
TRENDING NOW

Bris­tol My­ers out­lines ‘about 12’ pipeline cuts as it ex­e­cutes ma­jor cut­backs

Up­dat­ed: Bris­tol My­ers plans $1.5B in cost cuts, in­clud­ing 2,200 jobs, as CEO promis­es more ‘ag­ile’ com­pa­ny

Drug and biotech com­pa­nies join lob­by­ing push on Chi­na bill as scruti­ny of WuXi con­tin­ues

An­oth­er quar­ter, an­oth­er Keytru­da win for Mer­ck

De­spite on­col­o­gy cut­backs, Sanofi isn’t out of the game yet with ear­ly as­sets

Re­gen­eron and Mam­moth strike $100M deal to pair tiny CRISPR ed­i­tors with new de­liv­ery idea

A service from the Financial Times